J
Joao Victor Machado Alessi
Researcher at Harvard University
Publications - 67
Citations - 574
Joao Victor Machado Alessi is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 22 publications receiving 134 citations. Previous affiliations of Joao Victor Machado Alessi include Adma & University of São Paulo.
Papers
More filters
Journal ArticleDOI
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Biagio Ricciuti,Kathryn C. Arbour,Jessica J. Lin,Amir Vajdi,Natalie I. Vokes,Lingzhi Hong,Jianjun Zhang,Michael Y. Tolstorukov,Yvonne Y. Li,Yvonne Y. Li,Liam F. Spurr,Liam F. Spurr,Andrew D. Cherniack,Andrew D. Cherniack,Gonzalo Recondo,Giuseppe Lamberti,Xinan Wang,Deepti Venkatraman,Joao Victor Machado Alessi,Victor Vaz,Hira Rizvi,Jacklynn V. Egger,Andrew J. Plodkowski,Sara Khosrowjerdi,Subba R. Digumarthy,Hye Sun Park,Nuno Vaz,Mizuki Nishino,Lynette M. Sholl,David A. Barbie,Mehmet Altan,John V. Heymach,Ferdinandos Skoulidis,Justin F. Gainor,Matthew D. Hellmann,Mark M. Awad +35 more
TL;DR: In this paper, clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent and combined cohorts.
Journal ArticleDOI
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti,Xinan Wang,Joao Victor Machado Alessi,Hira Rizvi,Navin R. Mahadevan,Yvonne Y. Li,Andrew Polio,James Lindsay,Renato Umeton,Rileen Sinha,Natalie I. Vokes,Gonzalo Recondo,Giuseppe Lamberti,Marissa N. Lawrence,V. Vaz,Giulia Costanza Leonardi,Andrew J. Plodkowski,Hersh Gupta,Andrew D. Cherniack,Michael Y. Tolstorukov,Bijaya Sharma,Kristen Felt,Justin F. Gainor,Arvind Ravi,Gad Getz,Kurt A. Schalper,Brian Henick,Patrick M. Forde,Valsamo Anagnostou,Pasi A. Jänne,Eliezer M. Van Allen,Mizuki Nishino,Lynette M. Sholl,David C. Christiani,Xihong Lin,Scott J. Rodig,Matthew D. Hellmann,Mark M. Awad +37 more
TL;DR: It is suggested that in NSCLC, a high number of nonsynonymous tumor mutations is associated with immune cell infiltration and inflammatory T-cell expression signatures, leading to increased sensitivity to PD-1/PD-L1 inhibition across PD-L 1 expression subgroups.
Journal ArticleDOI
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Franciele Hinterholz Knebel,Fabiana Bettoni,Andrea K. Shimada,Manoel Cruz,Joao Victor Machado Alessi,Marcelo V. Negrao,Luiz F. L. Reis,Artur Katz,Anamaria A. Camargo +8 more
TL;DR: Monitoring of patients with EGFR-exon19del positive NSCLC and quantification of the original EGFR activation mutation, instead of the resistance mutations, can be efficiently used to monitor response to osimertinib, allowing early detection of AR.
Journal ArticleDOI
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Biagio Ricciuti,Greg Jones,Mariano Severgnini,Joao Victor Machado Alessi,Gonzalo Recondo,Marissa N. Lawrence,Tim Forshew,Christine A. Lydon,Mizuki Nishino,Michael Cheng,Mark M. Awad +10 more
TL;DR: In this paper, the authors studied the effect of changes in circulating tumor DNA (ctDNA) levels after initiation of first-line pembrolizumab±chemotherapy in non-small cell lung cancer (NSCLC) patients.
Journal ArticleDOI
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Joao Victor Machado Alessi,Biagio Ricciuti,Elizabeth Jimenez-Aguilar,Fangxin Hong,Zihan Wei,Mizuki Nishino,Andrew J. Plodkowski,Peter Sawan,Jia Luo,Hira Rizvi,Brett W. Carter,John V. Heymach,Mehmet Altan,Matthew D. Hellmann,Mark M. Awad +14 more
TL;DR: A subset of patients with NSCLC and an ECOG PS of 2 can respond to first-line pembrolizumab, however, clinical outcomes in this population are often poor and use of second-line systemic therapy is infrequent.